• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Foghorn Therapeutics Inc. - Common Stock (NQ:FHTX)

    4.360 +0.360 (+9.00%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 7, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 165,658
    Open 4.040
    Bid (Size) 4.000 (200)
    Ask (Size) 4.400 (2,200)
    Prev. Close 4.000
    Today's Range 3.860 - 4.430
    52wk Range 2.945 - 9.700
    Shares Outstanding 36,936,886
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    This Aardvark Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday
     
    Via Benzinga
    Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -5.0%
    -5.0%
    1 Month
    -3.1%
    -3.1%
    3 Month
    -4.8%
    -4.8%
    6 Month
    +3.8%
    +3.8%
    1 Year
    -52.1%
    -52.1%

    More News

    Read More
    These stocks are gapping in today's session
    Via Chartmill
    Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    This PayPal Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Wednesday
    Via Benzinga
    Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Why PVH Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    This Worthington Enterprises Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
    Via Benzinga
    Foghorn Therapeutics Highlights Program Progress and Strategic Objectives for 2025
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Why Foghorn Therapeutics (FHTX) Stock Is Trading Lower
    Via Benzinga
    Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities
    From Foghorn Therapeutics, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Foghorn Therapeutics Inc. - Common Stock publicly traded?
    Yes, Foghorn Therapeutics Inc. - Common Stock is publicly traded.
    What exchange does Foghorn Therapeutics Inc. - Common Stock trade on?
    Foghorn Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Foghorn Therapeutics Inc. - Common Stock?
    The ticker symbol for Foghorn Therapeutics Inc. - Common Stock is FHTX on the Nasdaq Stock Market
    What is the current price of Foghorn Therapeutics Inc. - Common Stock?
    The current price of Foghorn Therapeutics Inc. - Common Stock is 4.360
    When was Foghorn Therapeutics Inc. - Common Stock last traded?
    The last trade of Foghorn Therapeutics Inc. - Common Stock was at 11/07/25 04:00 PM ET
    What is the market capitalization of Foghorn Therapeutics Inc. - Common Stock?
    The market capitalization of Foghorn Therapeutics Inc. - Common Stock is 161.04M
    How many shares of Foghorn Therapeutics Inc. - Common Stock are outstanding?
    Foghorn Therapeutics Inc. - Common Stock has 161M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.